The Series B Crunch
Physical therapy tech has a peculiar problem in India. Strong Series A exits exist—but Series B is a graveyard. Companies plateau at $200K-$400K MRR because they solve a problem hospitals and insurers don't yet value at institutional scale.
The math is simple. A Series A raised $1.5M-$3M between 2020-2022. Burn was high. Growth was strong. But at Series B, VCs ask a different question: can this company defend market share against 3-4 well-funded competitors?
The answer today is often no.
What VCs Actually Measure
Unit Economics First
Forget revenue growth. VCs want gross margins. A good PT tech Series B shows 75%+ gross margins. This means your platform cost per session is below ₹150-200, even after paying physiotherapists 60-70% of session revenue.
Compare this to logistics or lending startups. They celebrate 40% margins at scale. PT tech margins are higher because the service is digital-first. If your margins are below 65%, your unit is broken. No Series B investor will fix it for you.
Measure this monthly. Track it by channel. If B2B corporate wellness margins are 80% but B2C direct margins are 45%, your narrative breaks at Series B. VCs will ask: why not double down on B2B?
Retention and Churn
PT outcomes take 8-12 weeks minimum. Churn before week 8 is not patient preference. It's product failure.
Series A accepts 8-10% monthly churn on B2C because growth masks it. Series B does not. Institutional investors want monthly churn below 5% for B2C and below 3% for B2B contracts.
Build your dashboard to track: cohort-based retention at week 4, week 8, week 12. If 60% of patients don't return after week 8, your outcome proof is weak. No insurance company will partner with you.
Multi-channel retention matters here. If your B2B corporate wellness arm has 2% quarterly churn but B2C direct has 35%, you've found your Series B narrative: you're a B2B platform, not a consumer app. Own it.
CAC and Payback Period
Series A allows high CAC because VCs fund burn. Series B demands payback under 6 months for B2B and under 12 months for B2C.
If your CAC is ₹1,500 and average session value is ₹300, you need 5 sessions to break even. That's 5-6 weeks. If churn hits 10% monthly, you lose money on that customer.
Series B investors will stress-test this relentlessly. Build a CAC waterfall by channel. Track payback period weekly. If corporate wellness CAC is ₹800 (through HR partnerships) with payback in 3 months, that's your wedge. Lead with it.
Clinical Outcomes Data
This is not optional anymore. Insurance companies and large corporates now require Range of Motion (ROM) improvement, pain score reduction (VAS scale), or return-to-work metrics.
Collect it systematically. A Series B candidate has data on 500+ completed therapy courses showing: average 35-40% improvement in pain scores, 25-30% improvement in ROM, 85%+ return-to-work rates.
Without this, you're a scheduling app. With it, you're a clinical platform. The valuation difference is 3-4x.
The India Stack Moat
Physical therapy tech startups that integrate Aadhaar-based authentication, UPI payments, and NDHM health records are building defensibility Series A companies missed.
Why? Because insurance reimbursement in India increasingly requires digital audit trails. NDHM integration means your patient records are on the national health cloud—insurers trust this.
Aadhaar-based gym/clinic verification means you can prevent fraud at scale. UPI means no payment disputes. This stack is your moat against larger, slower competitors.
SeriesB investors now expect this. If you haven't mapped NDHM integration into your 18-month roadmap, reframe it now.
The Multi-Channel Narrative
The strongest Series B candidates have three channels: B2B corporate wellness, B2B insurance/TPA partnerships, and direct-to-consumer.
Corporate wellness (₹50-200 ARPU annually per employee) is sticky but capped. Insurance networks scale but have 30-40% lower margins. Direct-to-consumer is high-margin but has churn risk.
A company with 40% revenue from corporate, 35% from insurance, 25% from direct has institutional appeal. If any channel is above 60%, you're vulnerable.
Build this narrative early. Don't chase GMV. Build defensibility.
Timeline and Milestones
Assum you're closing Series A now with $2.5M capital. Here's the 18-month Series B calendar:
Months 1-3: Lock unit economics. Hit 72%+ gross margins. Get to $100K MRR from one channel.
Months 4-6: Pilot with insurance partner (ICICI Lombard, Bajaj, or a TPA). Collect outcomes data. Build NDHM integration.
Months 7-12: Launch corporate wellness vertical through an HR partner (Peoplebox, Aon, or Willis). Hit 3x channel diversity.
Months 13-18: Scale to $400K+ MRR. Lock retention at <5% monthly churn. Close a named corporate enterprise customer worth >₹10L annually.
By month 15, you should have: (1) clinical outcomes data on 1000+ patients, (2) three revenue channels, (3) <3% quarterly churn on B2B, (4) gross margins at 72%+.
That's your Series B deck.
The Investor Question
VCs will ask: "Why doesn't a hospital or diagnostic chain build this?"
Your answer: "Because they optimize for clinic utilization, not patient outcomes. We optimize for patient outcomes—which aligns with insurance incentives and corporate wellness ROI. They can't move fast enough to compete."
If you can't answer this in 2 sentences, your narrative isn't ready.
The Timing Lens
India's digital health reimbursement is maturing. ICICI, Bajaj, and Acko now reimburse telehealth and digital therapy explicitly. This window closes in 18-24 months as competition enters.
Your Series B timeline isn't arbitrary. It's a race to be the distribution partner insurers and corporates lock in before the next 5 competitors close Series A.
Move fast. Build outcomes. Own B2B. That's the Series B playbook for PT tech in India.